keyword
MENU ▼
Read by QxMD icon Read
search

blood, hematology, lymphoma, multiple Myeloma, chronic myeloid leukemia

keyword
https://www.readbyqxmd.com/read/27761889/microrna-155-in-serum-derived-extracellular-vesicles-as-a-potential-biomarker-for-hematologic-malignancies-a-short-report
#1
Antonella Caivano, Francesco La Rocca, Vittorio Simeon, Marco Girasole, Simone Dinarelli, Ilaria Laurenzana, Angelo De Stradis, Luciana De Luca, Stefania Trino, Antonio Traficante, Giovanni D'Arena, Giovanna Mansueto, Oreste Villani, Giuseppe Pietrantuono, Luca Laurenti, Luigi Del Vecchio, Pellegrino Musto
PURPOSE: The use of extracellular vesicles (EVs) from body fluids as "liquid biopsies" is emerging as a promising approach for the diagnosis, prognosis and therapeutic monitoring of cancer patients. MicroRNA-155 (miR155), a non-coding transcript of the B-cell integration cluster (BIC) gene, has been reported to play a critical role in the pathogenesis of several types of hematologic malignancies (HMs) in which high miR155 levels have been found. At yet, however, the EV miR155 level and its putative clinical relevance in sera of HM patients have not been reported...
October 19, 2016: Cellular Oncology (Dordrecht)
https://www.readbyqxmd.com/read/27535422/improved-clinical-outcomes-of-rhg-csf-mobilized-blood-and-marrow-haploidentical-transplantation-compared-to-propensity-score-matched-rhg-csf-primed-peripheral-blood-stem-cell-haploidentical-transplantation-a-multicenter-study
#2
Xiangyu Zhao, Feng Gao, Xiaohui Zhang, Yu Wang, Lanping Xu, Kaiyan Liu, Xiaosu Zhao, Yingjun Chang, Han Wei, Huan Chen, Yuhong Chen, Zhengfan Jiang, Xiaojun Huang
The effects of haploidentical rhG-CSF-mobilized blood and marrow transplantation (HBMT) on hematological malignances are well established. Previous prospective single-center studies have demonstrated better survival after HBMT versus haploidentical rhG-CSF-mobilized peripheral blood stem cell transplantation (HPBSCT) for acute leukemia (AL) not in remission (NR) or in more than the second complete remission (>CR2). To test the hypothesis that HBMT is still superior to HPBSCT for patients with AL, multiple myeloma (MM), or non-Hodgkin lymphoma (NHL) in CR1/CR2 and for patients with chronic myeloid leukemia in the first and second chronic phase lacking a matched donor, we designed a propensity score method-based multicenter study...
August 17, 2016: Science China. Life Sciences
https://www.readbyqxmd.com/read/26915519/distribution-and-features-of-hematological-malignancies-in-eastern-morocco-a-retrospective-multicenter-study-over-5-years
#3
Mounia Elidrissi Errahhali, Manal Elidrissi Errahhali, Redouane Boulouiz, Meryem Ouarzane, Mohammed Bellaoui
BACKGROUND: Hematological malignancies (HM) are a public health problem. The pattern and distribution of diagnosed hematological cancers vary depending on age, sex, geography, and ethnicity suggesting the involvement of genetic and environmental factors for the development of these diseases. To our knowledge, there is no published report on HM in the case of Eastern Morocco. In this report we present for the first time the overall pattern of HM for this region. METHODS: Retrospective descriptive study of patients diagnosed with HM between January 2008 and December 2012 in three centres in Eastern Morocco providing cancer diagnosis, treatment or palliative care services...
2016: BMC Cancer
https://www.readbyqxmd.com/read/26452331/hematopoietic-stem-cell-transplantation-in-the-eastern-mediterranean-region-emro-2011-2012-a-comprehensive-report-on-behalf-of-the-eastern-mediterranean-blood-and-marrow-transplantation-group-embmt
#4
Mahmoud Aljurf, Amr Nassar, Amir Ali Hamidieh, Alaa Elhaddad, Rose-Marie Hamladji, Ali Bazarbachi, Ahmed Ibrahim, Tarek Ben Othman, Fawzi Abdel-Rahman, Amal Alseraihy, Omar Fahmy, Ayad Ahmed Hussein, Abdulaziz Alabdulaaly, Salman Adil, Salam Salim Amur Alkindi, Mohamed Bayoumy, David Dennison, Mohamed Amine Bekadja, Ahmed Nacer Redhouane, Walid Rasheed, Ahmed AlSagheir, Reem Alsudairy, Saloua Ladeb, Said Benchekroun, Mani Ramzi, Parvez Ahmed, Hassan ElSolh, Syed Osman Ahmed, Fazal Hussain, Ardeshir Ghavamzadeh
OBJECTIVE/BACKGROUND: The Eastern Mediterranean Blood and Marrow Transplantation (EMBMT) group has accumulated over 31 years of data and experience in hematopoietic stem cell transplantation (HSCT), particularly in hemoglobinopathies, severe aplastic anemia, inherited metabolic and immune disorders, in addition to a wide array of hematologic malignancies unique to this region. A regional update in current HSCT trends is highly warranted. We studied the trends of HSCT activities in World Health Organization-Eastern Mediterranean (EMRO) region, surveyed by the EMBMT, between 2011 and 2012...
December 2015: Hematology/oncology and Stem Cell Therapy
https://www.readbyqxmd.com/read/26156801/high-serum-levels-of-extracellular-vesicles-expressing-malignancy-related-markers-are-released-in-patients-with-various-types-of-hematological-neoplastic-disorders
#5
Antonella Caivano, Ilaria Laurenzana, Luciana De Luca, Francesco La Rocca, Vittorio Simeon, Stefania Trino, Fiorella D'Auria, Antonio Traficante, Maddalena Maietti, Tiziana Izzo, Giovanni D'Arena, Giovanna Mansueto, Giuseppe Pietrantuono, Luca Laurenti, Pellegrino Musto, Luigi Del Vecchio
Many cell types release extracellular vesicles (EVs), including exosomes, microvesicles (MVs), and apoptotic bodies, which play a role in physiology and diseases. Presence and phenotype of circulating EVs in hematological malignancies (HMs) remain largely unexplored.The aim of this study was to characterize EVs in peripheral blood of HM patients compared to healthy subjects (controls). We isolated serum EVs from patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), Waldenstrom's macroglobulinemia (WM), Hodgkin's lymphoma (HL), multiple myeloma (MM), acute myeloid leukemia (AML), myeloproliferative neoplasms (MPNs), myelodysplastic syndromes (MDS), and controls...
December 2015: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://www.readbyqxmd.com/read/24908530/spectrum-of-hematological-malignancies-and-peripheral-cytopenias
#6
A Jha
BACKGROUND: Peripheral cytopenias such as anemia, thrombocytopenia, bicytopenia and pancytopenia are common peripheral blood findings in hematological malignances for which bone marrow evaluation is often required. The study was conducted to identify the spectrum of hematological malignancies in association with peripheral cytopenia. METHODS: One year retrospective study was conducted in Tribhuvan University Teaching Hospital. Data of bone marrow examination were retrieved from the archives of the hematology department and analyzed...
September 2013: Journal of Nepal Health Research Council
https://www.readbyqxmd.com/read/24833969/hematopoietic-neoplasias-in-horses-myeloproliferative-and-lymphoproliferative-disorders
#7
REVIEW
Ana Muñoz, Cristina Riber, Pablo Trigo, Francisco Castejón
Leukemia, i.e., the neoplasia of one or more cell lines of the bone marrow, although less common than in other species, it is also reported in horses. Leukemia can be classified according to the affected cells (myeloproliferative or lymphoproliferative disorders), evolution of clinical signs (acute or chronic) and the presence or lack of abnormal cells in peripheral blood (leukemic, subleukemic and aleukemic leukemia). The main myeloproliferative disorders in horses are malignant histiocytosis and myeloid leukemia, the latter being classified as monocytic and myelomonocytic, granulocytic, primary erythrocytosis or polycythemia vera and megakaryocytic leukemia...
2009: Journal of Equine Science
https://www.readbyqxmd.com/read/24454381/micrornas-as-haematopoiesis-regulators
#8
REVIEW
Ram Babu Undi, Ravinder Kandi, Ravi Kumar Gutti
The production of different types of blood cells including their formation, development, and differentiation is collectively known as haematopoiesis. Blood cells are divided into three lineages erythriod (erythrocytes), lymphoid (B and T cells), and myeloid (granulocytes, megakaryocytes, and macrophages). Haematopoiesis is a complex process regulated by several mechanisms including microRNAs (miRNAs). miRNAs are small RNAs which regulate the expression of a number of genes involved in commitment and differentiation of hematopoietic stem cells...
2013: Advances in Hematology
https://www.readbyqxmd.com/read/24053209/hematological-malignancies-role-of-mirnas-and-their-in-silico-aspects
#9
REVIEW
Ankur Omer, Navneet K Yadav, Poonam Singh, Rama K Singh
Hematological malignancies is a broad term that includes blood cell cancers including chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), acute myeloid leukemia (AML), Myelodysplastic syndrome, acute lymphocytic leukemia (ALL), multiple myelomas (MM) and lymphomas. miRNAs are ~22-nt long non-coding RNAs that play a very important role in gene regulation by binding to mRNA at their complementary sequence. These miRNAs are conceptually connected with various signal and pathway networks that make them capable of regulating various diseases including hematological malignancies...
September 2013: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/23580820/stem-cell-transplant-an-experience-from-eastern-india
#10
A Mukhopadhyay, P Gupta, J Basak, A Chakraborty, D Bhattacharyya, S Mukhopadhyay, U K Roy
BACKGROUND: Hematopoietic stem cell transplant using human leukocyte antigen (HLA)-matched sibling or unrelated bone marrow, or related or unrelated cord blood has been performed successfully to treat patients with different types of hematological malignancies, genetic disorders and hereditary immune deficiencies. Since 1983, stem cell transplantation has been carried out in different institutes of India. But, till then, no transplantation was performed in eastern India. MATERIALS AND METHODS: Our present study is reporting for the first time stem cell transplantation in eastern India...
October 2012: Indian Journal of Medical and Paediatric Oncology
https://www.readbyqxmd.com/read/22588328/metabolic-factors-and-blood-cancers-among-578-000-adults-in-the-metabolic-syndrome-and-cancer-project-me-can
#11
Gabriele Nagel, Tanja Stocks, Daniela Späth, Anette Hjartåker, Björn Lindkvist, Göran Hallmans, Håkan Jonsson, Tone Bjørge, Jonas Manjer, Christel Häggström, Anders Engeland, Hanno Ulmer, Randi Selmer, Hans Concin, Pär Stattin, Richard F Schlenk
We investigated associations between metabolic factors and blood cancer subtypes. Data on body mass index (BMI), blood pressure, blood glucose, total cholesterol, and triglycerides from seven prospective cohorts were pooled (n = 578,700; mean age = 44 years). Relative risks of blood cancers were calculated from Cox regression models. During mean follow-up of 12 years, 2,751 incident and 1,070 fatal cases of blood cancers occurred. Overall, higher BMI was associated with an increased blood cancer risk. In gender-specific subgroup analyses, BMI was positively associated with blood cancer risk (p = 0...
October 2012: Annals of Hematology
https://www.readbyqxmd.com/read/22352263/impact-of-stem-cell-source-on-allogeneic-stem-cell-transplantation-outcome-in-hematological-malignancies
#12
COMPARATIVE STUDY
Dragana Stamatović, Bela Balint, Ljiljana Tukić, Marija Elez, Olivera Tarabar, Milena Todorović, Gordana Ostojić, Zeljka Tatomirovic, Marika Ljubenov, Slobodan Marjanović, Milomir Malesević
BACKGROUND/AIM: Peripheral blood (PB) is used more frequently as a source of stem cells (SCs) for allogeneic transplantation. However, the influence of cell source on the clinical outcome of SC transplantation is not yet well established. The aim of this study was to compare the results of PBSC transplantation (PBSCT) with bone marrow transplantation (BMT) on the basis of engraftment, frequency and severity of immediate (mucositis, acute Graft versus Host Disease--aGvHD) and delayed (chronic GvHD--cGvHD) complications, as well as transplant-related mortality (TRM), transfusion needs, relapses and overall survival (OS)...
December 2011: Vojnosanitetski Pregled. Military-medical and Pharmaceutical Review
https://www.readbyqxmd.com/read/20381970/role-of-donor-lymphocyte-infusions-in-relapsed-hematological-malignancies-after-stem-cell-transplantation-revisited
#13
REVIEW
Abhinav Deol, Lawrence G Lum
BACKGROUND: Treatment of relapsed hematological malignancies after an allogeneic peripheral blood stem cell transplant (SCT) is challenging. Donor lymphocyte infusion (DLI) from the stem cell donor is an attractive clinical option to salvage this group of patients. METHODS: We reviewed the important studies looking at donor lymphocyte infusion as a therapy for the treatment of hematological disorders that are either refractory to or have relapsed after allogeneic SCT...
November 2010: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/19151562/-clinical-values-of-biomarkers-in-hematopoietic-malignancies
#14
Tatsuya Kawaguchi, Kisato Nosaka
Hematopoietic malignancies include leukemia, lymphoma and multiple myeloma. These diseases are primarily diagnosed on the basis of morphological features of affected cells, which appear in peripheral blood, bone marrow and lymphoid organs. By taking advantage of the repetitive accessibility of the neoplastic cells within the peripheral blood / and/or bone marrow aspirates, morphological tests are conducted not only for diagnosis but also for evaluation of clinical outcomes and prognosis, suggesting that the morphological features are considered as a clinical biomarker in hematopoietic malignancies...
January 2009: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/18573186/increased-acquired-activated-protein-c-resistance-in-unselected-patients-with-hematological-malignancies
#15
H F S Negaard, P O Iversen, B Ostenstad, M C Mowinckel, P M Sandset
BACKGROUND: We have previously found that activation of coagulation in patients with various hematological malignancies was apparently not initiated by tissue factor (TF). Acquired activated protein C (APC) resistance may be another mechanism responsible for such hypercoagulation, and has been demonstrated in patients with solid tumors, but not in patients with hematological malignancy. OBJECTIVE: To investigate acquired APC resistance in a hypercoagulable cohort of patients with hematological malignancies...
September 2008: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/18521506/hypercoagulability-in-patients-with-haematological-neoplasia-no-apparent-initiation-by-tissue-factor
#16
MULTICENTER STUDY
Helene F S Negaard, Per Ole Iversen, Bjørn Østenstad, Nina Iversen, Pål A Holme, Per Morten Sandset
Patients with haematological malignancies carry increased risk of venous thrombosis (VT). However, the mechanisms that link these malignancies to activated coagulation have not been fully identified. Since anti-haemostatic agents are studied in clinical trials for their potential to prolong survival in cancer patients, a detailed characterisation of haemostatic markers in cancer subtypes is needed. Hence, in this study, we measured the plasma concentrations and mRNA expression in blood mononuclear cells of haemostatic parameters in 93 patients with haematological neoplasias (acute myeloid leukaemia, chronic lymphatic leukaemia, multiple myeloma, and non-Hodgkin's lymphoma) before start and after completion of cancer therapy...
June 2008: Thrombosis and Haemostasis
https://www.readbyqxmd.com/read/17234016/economic-evaluations-of-leukemia-a-review-of-the-literature
#17
REVIEW
Frida Kasteng, Patrik Sobocki, Christer Svedman, Jonas Lundkvist
OBJECTIVES: Leukemia, together with lymphoma and multiple myeloma, are hematological malignancies, malignancies of the blood-forming organs. There are four major types of leukemia: acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), and chronic lymphocytic leukemia (CLL). There is a growing amount of literature of the health economic aspects of leukemia. However, no comprehensive review is yet performed on the health economic evidence for the disease...
2007: International Journal of Technology Assessment in Health Care
https://www.readbyqxmd.com/read/16479825/-suppressive-effect-of-high-dose-chemotherapy-hdc-on-the-clonal-growth-of-grafted-peripheral-blood-granulocyte-progenitors-is-reduced-72-hours-after-completion-of-hdc
#18
Maria Kozłowska-Skrzypczak, Janusz Hansz, Krzysztof Sawiński, Mieczysław Komarnicki
Hematopoietic stem cells (HSC) transplantations are usually performed 24-48 hours after the end od high-dose chemotherapy (HDC). It is possible, however, that at that time the transplanted HSC can be affected by the administered drugs. We report the results obtained in 30 patients (pts) with hematological malignancies (multiple myeloma - 14, Hodgkin's disease -6, non-Hodgkin's lymphomas -4, chronic myeloid leukemia -6) treated with HDC with peripheral blood stem cell transplantation (PBSCT). The following HDC regimens were applied: melphalan - 14, Dexa-BEAM (dexamethasone, BCNU, etoposide, cytarabine, melphalan) - 10 and BuCy2 (busulfan, cyclophosphamide) - 6...
May 2005: Polskie Archiwum Medycyny Wewnętrznej
https://www.readbyqxmd.com/read/15762065/an-experience-with-sixty-cases-of-haematological-malignancies-a-clinico-haematological-correlation
#19
REVIEW
Muhammad Idris, S H Shah, Jamila Fareed, Nasreen Gul
BACKGROUND: Haematological malignancies are not uncommon in our area. Due to inadequate diagnostic facilities and lack of health education they are diagnosed at an advanced stage when treatment is either impossible or very difficult. In our study, sixty patients with haematological malignancies were studied from 1-1-1999 to 1-1-2001, at Ayub Teaching Hospital. Abbottabad. METHODS: Patients were interviewed in detail, a thorough physical examination and blood tests including haemoglobin estimation, total and differential leukocyte count, platelets count, reticulocyte count and blood film examination was done on each patient...
October 2004: Journal of Ayub Medical College, Abbottabad: JAMC
https://www.readbyqxmd.com/read/15370258/identification-of-a-circulating-soluble-form-of-cd80-levels-in-patients-with-hematological-malignancies
#20
B D Hock, G C Starling, W N Patton, N Salm, K Bond, L T McArthur, J L McKenzie
The release of soluble forms of CD80 provides a potentially powerful mechanism for the modulation of anti-tumor responses. In this report we investigated whether a soluble form of CD80 (sCD80) circulates in vivo and whether levels are altered in patients with hematological malignancies. Circulating sCD80 was detected by ELISA in all normal donor (0.024-0.318 ng/ml) and patient (0.02-3.75 ng/ml) blood analyzed. The majority of acute myeloid leukemia (13/17) and multiple myeloma (11/12) patients had normal sCD80 levels...
October 2004: Leukemia & Lymphoma
keyword
keyword
78468
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"